Source 1primary paper2026MED
Toolkit/m10@T-NVs
m10@T-NVs
Also known as: IL-10 mRNA-loaded T-NVs
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
The interleukin-10 anti-inflammatory cytokine mRNA (IL-10 mRNA) was encapsulated in lipid nanoparticles, which were fused with nanovesicles derived from mesenchymal stem cells (NVs) and functionalized with cardiac-targeting peptides (T peptides) to form IL-10 mRNA-loaded T-NVs (m10@T-NVs).
Usefulness & Problems
Why this is useful
m10@T-NVs are IL-10 mRNA-loaded nanovesicles generated by fusing mRNA-containing lipid nanoparticles with mesenchymal stem cell-derived nanovesicles and adding cardiac-targeting peptides. In this paper they serve as the vesicular component of the final magnetic carrier.; vesicle-based cardiac-targeted mRNA carrier construction
Source:
m10@T-NVs are IL-10 mRNA-loaded nanovesicles generated by fusing mRNA-containing lipid nanoparticles with mesenchymal stem cell-derived nanovesicles and adding cardiac-targeting peptides. In this paper they serve as the vesicular component of the final magnetic carrier.
Source:
vesicle-based cardiac-targeted mRNA carrier construction
Problem solved
It provides a hybrid vesicle carrier format for loading and targeting IL-10 mRNA toward injured cardiac tissue. The abstract positions it as an intermediate toward the dual-active magnetic system.; packaging IL-10 mRNA into a peptide-functionalized nanovesicle carrier for cardiac delivery
Source:
It provides a hybrid vesicle carrier format for loading and targeting IL-10 mRNA toward injured cardiac tissue. The abstract positions it as an intermediate toward the dual-active magnetic system.
Source:
packaging IL-10 mRNA into a peptide-functionalized nanovesicle carrier for cardiac delivery
Problem links
packaging IL-10 mRNA into a peptide-functionalized nanovesicle carrier for cardiac delivery
LiteratureIt provides a hybrid vesicle carrier format for loading and targeting IL-10 mRNA toward injured cardiac tissue. The abstract positions it as an intermediate toward the dual-active magnetic system.
Source:
It provides a hybrid vesicle carrier format for loading and targeting IL-10 mRNA toward injured cardiac tissue. The abstract positions it as an intermediate toward the dual-active magnetic system.
Published Workflows
Objective: Engineer a dual-active magnetic nanocarrier for efficient and spatially precise IL-10 mRNA delivery to injured cardiac tissue after myocardial infarction.
Why it works: The workflow combines vesicle-based and antibody/magnetic targeting features so that IL-10 mRNA cargo is packaged into peptide-functionalized nanovesicles and then magnetically guided to injured myocardium using anti-MLC3- and CD63-enabled magnetic assembly.
cardiac-targeting peptide-mediated localizationanti-MLC3 injured-myocardium targetingCD63-mediated assembly of vesicles with magnetic nanoparticlesexternal magnetic field-guided accumulationIL-10-mediated anti-inflammatory signalinglipid nanoparticle encapsulation of mRNAfusion of lipid nanoparticles with mesenchymal stem cell-derived nanovesiclesclick-chemistry antibody conjugation to magnetic nanoparticles
Stages
- 1.Build IL-10 mRNA-loaded peptide-functionalized nanovesicles(library_build)
This stage creates the vesicular carrier component that packages IL-10 mRNA and adds cardiac-targeting peptide functionality before magnetic assembly.
Selection: Assembly of IL-10 mRNA-loaded T-NVs by fusing IL-10 mRNA lipid nanoparticles with mesenchymal stem cell-derived nanovesicles and adding cardiac-targeting peptides
- 2.Functionalize magnetic nanoparticles for injured-cardiac targeting(library_build)
This stage equips magnetic nanoparticles to bind CD63-positive vesicle components and target damaged myocardial tissue through MLC3 recognition.
Selection: Conjugation of azide-modified anti-CD63 and anti-MLC3 antibodies to magnetic nanoparticles via click chemistry
- 3.Assemble dual-active magnetic nanovesicles(library_build)
This stage produces the final composite carrier that integrates vesicle targeting and magnetic localization functions.
Selection: Combination of m10@T-NVs with functionalized magnetic nanoparticles via CD63 interactions to form m10@T-MNVs
- 4.Characterize assembled nanocarrier(functional_characterization)
This stage verifies that the intended functionalization and assembly steps succeeded before biological testing.
Selection: Confirmation of nanovesicle and magnetic nanoparticle functionalization
- 5.Test magnetic targeting and delivery efficiency in injured cardiac settings(confirmatory_validation)
This stage checks whether the assembled carrier actually localizes to injured cardiac targets and improves delivery before therapeutic interpretation.
Selection: Accumulation in H2O2-induced injured cardiomyocytes and damaged cardiac regions under an external magnetic field
- 6.Evaluate therapeutic efficacy in mouse myocardial infarction(in_vivo_validation)
This stage validates whether targeted delivery translates into therapeutic benefit in myocardial infarction.
Selection: Enhanced intramyocardial IL-10 mRNA expression and downstream anti-inflammatory and tissue-protective effects in a mouse MI model
Steps
- 1.Encapsulate IL-10 mRNA in lipid nanoparticles
Package the therapeutic mRNA cargo before fusion into nanovesicles.
The abstract states that IL-10 mRNA was first encapsulated in lipid nanoparticles before those particles were fused with mesenchymal stem cell-derived nanovesicles.
- 2.Fuse IL-10 mRNA lipid nanoparticles with mesenchymal stem cell-derived nanovesicles and functionalize with cardiac-targeting peptidesengineered carrier intermediate
Generate IL-10 mRNA-loaded T-NVs as the vesicular targeting component.
This follows mRNA encapsulation because the loaded lipid nanoparticles are the material fused into nanovesicles to create m10@T-NVs.
- 3.Conjugate azide-modified anti-CD63 and anti-MLC3 antibodies to magnetic nanoparticles via click chemistry
Create magnetic nanoparticles that can both associate with CD63-positive vesicle material and target injured myocardium.
The magnetic nanoparticles must be functionalized before they can be combined with m10@T-NVs to form the final magnetic nanovesicle construct.
- 4.Combine m10@T-NVs with functionalized magnetic nanoparticles via CD63 interactions to form m10@T-MNVsfinal engineered carrier assembly
Produce the dual-active magnetic nanocarrier used for targeting and therapy.
This assembly depends on prior preparation of both the m10@T-NV intermediate and the antibody-functionalized magnetic nanoparticles.
- 5.Characterize m10@T-MNVs to confirm nanovesicle and magnetic nanoparticle functionalizationengineered carrier under characterization
Verify successful functionalization and assembly of the final carrier.
Characterization is reported before biological performance claims and serves as confirmation that the intended construct was produced.
- 6.Assess accumulation of m10@T-MNVs in injured cardiomyocytes and damaged cardiac regions under an external magnetic fieldcarrier under targeting evaluation
Determine whether magnetic guidance improves localization and delivery efficiency in injured cardiac settings.
This targeting test follows construct characterization and precedes in vivo therapeutic interpretation because the workflow aims to show that the carrier reaches injured tissue efficiently.
- 7.Administer m10@T-MNVs in a mouse myocardial infarction model and measure intramyocardial IL-10 expression and downstream therapeutic effectstherapeutic delivery system
Test whether targeted delivery of IL-10 mRNA produces anti-inflammatory and tissue-protective effects in vivo.
This is the highest-fidelity validation stage because it tests whether the engineered targeting strategy translates into therapeutic benefit in an MI animal model.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
antibody-mediated vesicle couplingmagnetic guidancemrna deliverypeptide-mediated tissue targetingTechniques
No technique tags yet.
Target processes
No target processes tagged yet.
Input: Magnetic
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationimplementation constraint: payload burdenoperating role: actuator
The construct requires IL-10 mRNA, lipid nanoparticles, mesenchymal stem cell-derived nanovesicles, and T-peptide functionalization. It is later combined with functionalized magnetic nanoparticles to make the final system.; requires fusion of IL-10 mRNA-loaded lipid nanoparticles with mesenchymal stem cell-derived nanovesicles; requires cardiac-targeting peptide functionalization
The abstract does not show that this component alone achieves the same targeting gain reported for the magnetically guided final construct.; the abstract does not report standalone in vivo efficacy of m10@T-NVs apart from the magnetic composite
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
m10@T-MNVs are formed by combining IL-10 mRNA-loaded T-NVs with magnetic nanoparticles functionalized with azide-modified anti-CD63 and anti-MLC3 antibodies via CD63 interactions.
Under an external magnetic field, m10@T-MNVs showed a 4.5-fold increase in accumulation in H2O2-injured cardiomyocytes and damaged cardiac regions.
accumulation increase 4.5 fold
A dual-active magnetic nanocarrier for targeted mRNA delivery to damaged cardiovascular tissue was engineered.
In a mouse model of myocardial infarction, m10@T-MNV administration enhanced intramyocardial IL-10 mRNA expression and cytokine production and was associated with M2 macrophage polarization, reduced tissue injury, apoptosis, fibrosis, and pathological myocardial remodeling.
Approval Evidence
1 source1 linked approval claimfirst-pass slug m10-t-nvs
The interleukin-10 anti-inflammatory cytokine mRNA (IL-10 mRNA) was encapsulated in lipid nanoparticles, which were fused with nanovesicles derived from mesenchymal stem cells (NVs) and functionalized with cardiac-targeting peptides (T peptides) to form IL-10 mRNA-loaded T-NVs (m10@T-NVs).
Source:
compositionsupports
m10@T-MNVs are formed by combining IL-10 mRNA-loaded T-NVs with magnetic nanoparticles functionalized with azide-modified anti-CD63 and anti-MLC3 antibodies via CD63 interactions.
Source:
Comparisons
Source-stated alternatives
The abstract mentions lipid nanoparticles alone as an encapsulation component but does not directly compare m10@T-NVs against other named vesicle or nanoparticle carriers.
Source:
The abstract mentions lipid nanoparticles alone as an encapsulation component but does not directly compare m10@T-NVs against other named vesicle or nanoparticle carriers.
Source-backed strengths
combines lipid nanoparticle mRNA encapsulation with mesenchymal stem cell-derived nanovesicles; includes cardiac-targeting peptide functionalization
Source:
combines lipid nanoparticle mRNA encapsulation with mesenchymal stem cell-derived nanovesicles
Source:
includes cardiac-targeting peptide functionalization
Compared with lipid nanoparticle
The abstract mentions lipid nanoparticles alone as an encapsulation component but does not directly compare m10@T-NVs against other named vesicle or nanoparticle carriers.
Shared frame: source-stated alternative in extracted literature
Strengths here: combines lipid nanoparticle mRNA encapsulation with mesenchymal stem cell-derived nanovesicles; includes cardiac-targeting peptide functionalization.
Relative tradeoffs: the abstract does not report standalone in vivo efficacy of m10@T-NVs apart from the magnetic composite.
Source:
The abstract mentions lipid nanoparticles alone as an encapsulation component but does not directly compare m10@T-NVs against other named vesicle or nanoparticle carriers.
Compared with lipid nanoparticles
The abstract mentions lipid nanoparticles alone as an encapsulation component but does not directly compare m10@T-NVs against other named vesicle or nanoparticle carriers.
Shared frame: source-stated alternative in extracted literature
Strengths here: combines lipid nanoparticle mRNA encapsulation with mesenchymal stem cell-derived nanovesicles; includes cardiac-targeting peptide functionalization.
Relative tradeoffs: the abstract does not report standalone in vivo efficacy of m10@T-NVs apart from the magnetic composite.
Source:
The abstract mentions lipid nanoparticles alone as an encapsulation component but does not directly compare m10@T-NVs against other named vesicle or nanoparticle carriers.
Compared with LNP
The abstract mentions lipid nanoparticles alone as an encapsulation component but does not directly compare m10@T-NVs against other named vesicle or nanoparticle carriers.
Shared frame: source-stated alternative in extracted literature
Strengths here: combines lipid nanoparticle mRNA encapsulation with mesenchymal stem cell-derived nanovesicles; includes cardiac-targeting peptide functionalization.
Relative tradeoffs: the abstract does not report standalone in vivo efficacy of m10@T-NVs apart from the magnetic composite.
Source:
The abstract mentions lipid nanoparticles alone as an encapsulation component but does not directly compare m10@T-NVs against other named vesicle or nanoparticle carriers.
Ranked Citations
- 1.